Sign In
Buy CERE
$44.96
+0 (+0%)
At Close: Oct 30, 2024
LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel
LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel
LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel
LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel
CERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law Firm
04:26am, Thursday, 13'th Feb 2025
LOS ANGELES , Feb. 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel Therapeutic
The Schall Law Firm Invites Shareholders With Losses In Cerevel Therapeutics Holdings, Inc. To Join A Securities Fraud Investigation
07:00pm, Wednesday, 12'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel
CERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law Firm
06:21pm, Wednesday, 12'th Feb 2025
LOS ANGELES--(BUSINESS WIRE)--CERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law Firm.
AbbVie Completes Acquisition of Cerevel Therapeutics
08:23am, Thursday, 01'st Aug 2024
Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class,
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeuti
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeut
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeut
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeut
The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Are Invited To Join
11:00am, Thursday, 27'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeut
The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Owners Of CERE Shares Are Invited To Join
01:30pm, Wednesday, 26'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeut
